《儿科皮肤病学中生物制剂的实用指南》。
A Practical Guide to Using Biologics in Pediatric Dermatology.
机构信息
Temerty School of Medicine, University of Toronto, Toronto, ON, Canada.
Michael G. Degroote School of Medicine, McMaster University, Hamilton, ON, Canada.
出版信息
J Cutan Med Surg. 2024 Jan-Feb;28(1):59-67. doi: 10.1177/12034754231222415. Epub 2024 Jan 16.
Psoriasis, hidradenitis suppurativa (HS), atopic dermatitis (AD), and chronic spontaneous urticaria (CSU), are common, immune-mediated, chronic, inflammatory skin diseases that can affect the pediatric population. While there is adequate evidence supporting the use of biologics in pediatric patients, concerns regarding safety and efficacy amongst healthcare providers are not uncommon. However, new emerging evidence in this population highlights the safety of biologic therapy, making it crucial to review and establish a practical guide for their use. This article describes a methodological framework for initiating biologics in the management of pediatric psoriasis, HS, AD, and CSU, with a special focus on baseline work-up, monitoring, dosing, and considerations in this population.
银屑病、化脓性汗腺炎（HS）、特应性皮炎（AD）和慢性自发性荨麻疹（CSU）是常见的免疫介导性慢性炎症性皮肤病，可影响儿科人群。虽然有足够的证据支持生物制剂在儿科患者中的应用，但在医疗保健提供者中，对安全性和疗效的担忧并不少见。然而，该人群中出现的新证据强调了生物疗法的安全性，因此，审查并建立生物制剂使用的实用指南至关重要。本文描述了一种在管理儿科银屑病、HS、AD 和 CSU 中启动生物制剂的方法学框架，特别关注基线检查、监测、剂量和该人群中的注意事项。
Zotero 插件